Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Clinical characteristics, treatment modalities and outcome of coronavirus disease 2019 patients treated at thisday dome isolation and treatment centre, federal capital territory Abuja, Nigeria

Okogbenin et al., Nigerian Postgraduate Medical Journal, doi:10.4103/npmj.npmj_532_21
Sep 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now known with p < 0.00000000001 from 102 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Retrospective 300 COVID-19 patients in Nigeria treated with ivermectin, zinc, vitamin C, and azithromycin, reporting no deaths. Authors conclude that early treatment is critical.
Okogbenin et al., 3 Sep 2021, peer-reviewed, 13 authors.
This PaperIvermectinAll
Clinical characteristics, treatment modalities and outcome of coronavirus disease 2019 patients treated at thisday dome isolation and treatment centre, federal capital territory Abuja, Nigeria
Cyriloshomah Erameh, Sylvanusakhalufo Okogbenin, Olachikerendu Egbuta, Kellyohis Iraoyah, Joythelma Onyebujoh, Christianehigbor Erohubie, Akoloyohanna Jaggu, Raymond Onovo, Mercy Avbuluimen, Modupeolaajibike Odewale, Elizabethebosebhanlen Enigbe, Ehinomencordilia Ifada, Estherosemudiamen Okogbenin
Nigerian Postgraduate Medical Journal, doi:10.4103/npmj.npmj_532_21
The coronavirus disease 2019 (COVID-19) is a highly transmissible viral infection caused by a novel coronavirus named the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was first reported on 31 st
Conflicts of interest There are no conflicts of interest.
Aggarwal, Garcia-Telles, Aggarwal, Lavie, Lippi et al., Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States, Diagnosis (Berl)
Almazeedi, Al-Youha, Jamal, Al-Haddad, Al-Muhaini et al., Characteristics, risk factors and outcomes among the first consecutive 1096 patients diagnosed with COVID-19 in Kuwait, EClinicalMedicine
Arinola, Fashina, Ishola, Akinbola, Akinbile et al., Demographic attributes of COVID-19 patients in an Infectious Disease Center of Nigeria, Afr J Clin Exp Microbiol
Ashinyo, Duti, Dubik, Amegah, Kutsoati et al., Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: A retrospective cohort study, Pan Afr Med J
Badr, Incidence and recovery of smell and taste dysfunction in COVID-19 positive patients, Egypt J Otolaryngol
Barry, Almohaya, Alhijji, Akkielah, Alrajhi et al., Clinical characteristics and outcome of hospitalized COVID-19 patients in a MERS-CoV endemic area, J Epidemiol Glob Health
Bowale, Abayomi, Idris, Omilabu, Abdus-Salam et al., Clinical presentation, case management and outcomes for the first 32 COVID-19 patients in Nigeria, Pan Afr Med J
Chen, Zheng, Zhang, Zhang, Wu et al., Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China, Infection
Elimian, Ochu, Ebhodaghe, Myles, Crawford et al., Patient characteristics associated with COVID-19 positivity and fatality in Nigeria: Retrospective cohort study, BMJ Open
Elimian, Ochu, Ilori, Oladejo, Igumbor et al., Descriptive epidemiology of coronavirus disease 2019 in Nigeria, 27 February-6 June 2020, Epidemiol Infect
Erinoso, Wright, Bowale, Adejumo, Adesola, Clinical characteristics, predictors of symptomatic coronavirus disease 2019 and duration of hospitalisation in a cohort of 632 Patients in Lagos State, Nigeria, Niger Postgrad Med J
Hafeez, Ahmad, Siddqui, Ahmad, Mishra, A review of COVID-19 (Coronavirus Disease-2019) diagnosis, treatments and prevention, Eur J Med Oncol
Jibrin, Okwong, Maigari, Ballah, Umar et al., Clinical and laboratory characteristics of COVID-19 among adult patients admitted to the isolation centre at Abubakar Tafawa Balewa Teaching Hospital Bauchi, Northest Nigeria, Pan Afr Med J
Khan, Dogra, Miriyala, Salman, Ishtiaq et al., Clinical characteristics and outcomes of patients with Corona Virus Disease 2019 (COVID-19) at Mercy Health Hospitals
Klopfenstein, Zahra, Kadiane-Oussou, Lepiller, Royer et al., New loss of smell and taste: Uncommon symptoms in COVID-19 patients on Nord Franche-Comte cluster, France, Int J Infect Dis
Ohia, Bakarey, Ahmad, COVID-19 and Nigeria: Putting the realities in context, Int J Infect Dis
Osibogun, Balogun, Abayomi, Idris, Kuyinu et al., Outcomes of COVID-19 patients with comorbidities in southwest Nigeria, PLoS One
Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area, JAMA
Sohrabi, Alsafi, Neill, Khan, Kerwan et al., World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19), Int J Surg
Wang, Xin, Xiong, Yan, Cai et al., Clinical characteristics and outcomes of 421 patients with coronavirus disease 2019 treated in a mobile cabin hospital, Chest
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop